Navigation Links
Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference

BALTIMORE, Sept. 9 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, will present at Rodman & Renshaw's Eleventh Annual Healthcare Conference taking place September 9 - 11, 2009, at the New York Palace Hotel. The company's Chairman of the Board, Dr. David Sidransky, will present on Thursday, September 10, 2009, 2:50pm EDT in the Hubbard Salon (5th floor). Additional information regarding the conference can be found at

Expected to welcome 3,500 guests and include presentations by over five hundred companies, the conference will be attended by investors, venture capitalists, company executives, medical experts, scientists, and other industry leaders. To access a live audio webcast or the subsequent archived recording, log on to Please connect to the website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-K for the fiscal year ended April 30, 2009 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law.

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
2. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
3. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
4. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
5. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
6. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
7. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
8. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
9. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
10. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
11. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... a new, Good Manufacturing Practice (GMP) 10000 in the Santiago Marriott. The Global ... and is operated by a world-class team of qualified medical researchers and practitioners, ...
(Date:11/30/2015)... N.Y. , Nov. 30, 2015  Culprits ... by assistant chemistry professor Jan Halámek, is taking ...   --> ...   --> ... at UAlbany have discovered a straightforward concept for ...
(Date:11/30/2015)... HACKENSACK, N.J. , Nov. 30, 2015  Champions ... technology solutions and services to personalize the development and ... Ackerman , Chief Executive Officer, will be presenting at ... 2015 at 4:30pm Pacific Standard Time (PST).  The conference, ... Los Angeles, CA , will feature ...
(Date:11/30/2015)... , Nov. 30, 2015  AbbVie, is introducing ... focuses on a daily routine for managing the life-long ... medication can affect the way the body absorbs it ... their a daily routine are important. The goal of ... patients better manage their hypothyroidism by establishing a daily ...
Breaking Biology Technology:
(Date:10/29/2015)... Today, LifeBEAM , a leader ... a global leader in technical performance sports clothing ... advanced bio-sensing technology. The hat will allow fitness ... biometrics to improve overall training performance. As a ... bring together the most advanced technology, extensive understanding ...
(Date:10/27/2015)... 2015 Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ... , so that they can be quantitatively analyzed with ... Munich, Germany , October 28-29, 2015. SMI,s Automated ... mobile eye tracking videos created with SMI,s Eye ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
Breaking Biology News(10 mins):